GlaxoSmithKline (GSK) Reports Q1 EPS of GBP0.19; Lowers FY14 EPS Growth Outlook

GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of GBP0.19, versus GBP0.26 reported last year. Revenue for the quarter came in at GBP5.56 billion, versus GBP6.62 billion reported last year.

Full year 2014 core EPS now expected to be broadly similar to 2013, from prior growth expectations of 4 to 8 percent.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
• Unicycive Therapeutics, Inc (UNCY) Tops Q2 EPS by 42c
• Four key things investors will watch in Nvidia's earnings next week